← All earnings call summaries
Rubicon Research Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Q1 FY27 revenue INR534 Cr +51% y-y; EBITDA INR131 Cr +65% y-y; PAT INR85 Cr +95% y-y
- EBITDA margin guided upwards to 23% for FY27 from earlier 22-23%
- Gross margin improved sequentially by 140 bps to 67.7% despite input cost rise
- R&D spend at 10.9% of revenue; productivity at 5.5x; INR500 Cr spend guidance on track
- Pithampur facility FDA approved; ramp-up expected from Q1 CY27; significant expansion headroom
- Arinna acquisition contributed INR12 Cr revenue; EBITDA impact immaterial
- US manufacturing facility acquisition strategic; commercial operations to start CY27
- Management change: CFO Nitin Jajodia to Chief Commercial Officer; Rohit appointed CFO designate
- Specialty portfolio contributes 36% to gross profit; broad-based product growth continues
- Multiple analyst queries on product pipeline and AI adoption; management cautious on AI specifics
📄 Source: View original transcript (PDF)
Get Rubicon Research Limited earnings summaries on Telegram
Add Rubicon Research Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.